Thoratec Issues LVAD Guidelines; WorldHeart Announces June 8 FDA Panel
This article was originally published in The Gray Sheet
Thoratec expects to steadily improve infection and survival rates associated with the HeartMate XVE LVAD by issuing a series of "best practice" guidelines developed by the most experienced ventricular assist device implanters
You may also be interested in...
Arrow International's board of directors will assess the future commercial potential of its left-ventricular assist devices at a meeting April 6-7
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.